Anwar Michael Badruddoja, MD
Neurology · Tucson, AZNPI 1891779872
Payments from drug & device makers
Across 240 payments — averaging $5938.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$855K
- Genentech, Inc.$257K
- Biogen$170K
- E.r. Squibb & Sons, L.L.C.$105K
- Eisai Inc.$25K
- Beigene, Ltd.$8K
- plus $5K from 33 others
Across 10 payments — averaging $1175.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$12K
What the payments were for
- Consulting fees$2,82520%
- Speaking & faculty fees$5,08536%
- Travel & lodging$2,80820%
- Food & beverage$3,45924%
- Education$1161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 45 | $855,464 |
| Genentech, Inc. | 18 | $256,773 |
| Biogen | 39 | $169,687 |
| E.r. Squibb & Sons, L.L.C. | 8 | $105,322 |
| Eisai Inc. | 17 | $25,088 |
| Beigene, Ltd. | 8 | $7,933 |
| Kadmon Corporation LLC | 2 | $2,669 |
| AbbVie | 15 | $356 |
| Novartis | 12 | $227 |
| Amgen | 9 | $192 |
| Novocure Inc. | 1 | $147 |
| Silk Road Medical, Inc. | 1 | $142 |
| UCB, Inc. | 5 | $127 |
| Vanda Pharmaceuticals Inc. | 5 | $127 |
| Arbor Pharmaceuticals, Inc. | 5 | $118 |
| Sanofi | 4 | $101 |
| EMD Serono, Inc. | 4 | $82 |
| Pfizer | 5 | $75 |
| Argenx US, Inc. | 3 | $61 |
| Sumitomo Pharma America, Inc. | 6 | $55 |
| Jazz Pharmaceuticals Inc. | 2 | $54 |
| Bristol Myers Squibb | 3 | $49 |
| Servier Pharmaceuticals LLC | 2 | $46 |
| Lilly USA, LLC | 3 | $43 |
| TG Therapeutics, Inc. | 2 | $41 |
| Cycle Pharmaceuticals Inc | 2 | $37 |
| GT Medical Technologies, Inc | 1 | $35 |
| Neurocrine Biosciences, Inc. | 2 | $34 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Merz Pharmaceuticals, LLC | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Aucta Pharmaceuticals, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,425,265 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AubagioTeriflunomide | 16 | $149,978 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $124,714 |
| TecfideraDimethyl Fumarate | 13 | $120,817 |
| ZonegranZonisamide | 17 | $115,413 |
| Glatiramer Acetate | 40 | $87,355 |
| BriviactBrivaracetam | 41 | $80,269 |
| VimpatLacosamide | 40 | $53,567 |
| Nurtec OdtRimegepant Sulfate | 29 | $42,551 |
| KeppraLevetiracetam | 19 | $34,580 |
| XcopriCenobamate | 19 | $29,752 |
| LamictalLamotrigine | 13 | $28,134 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $23,233 |
| UbrelvyUbrogepant | 20 | $19,407 |
| Rufinamide | 12 | $18,390 |
| Lacosamide | 116 | $17,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack), Tecfidera | $169,687 | $245,53126 claims |
| SanofiAubagio | $101 | $149,97816 claims |
| UCB, Inc.Briviact, Vimpat | $127 | $133,83781 claims |
| PfizerNurtec Odt, Eliquis, Dilantin | $75 | $59,92470 claims |
| AbbVieUbrelvy | $356 | $19,40720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 neurology providers in Arizona.
Other neurology in Tucson
- Francisco ValdiviaTucson$1.4M
- Jeanette WendtTucson$557K
- Lloyd AndersonTucson$417K
- Geoffrey AhernTucson$384K
- Steven RapcsakTucson$327K
- Scott ShermanTucson$278K
- David WeidmanPhoenix$7.4M
- Hemant PandeyChandler$6.2M
- Stephen FlitmanPhoenix$4.4M
- Barry HendinPhoenix$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.